If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFusion Antibodies Regulatory News (FAB)

Share Price Information for Fusion Antibodies (FAB)

Share Price is delayed by 15 minutes
Get Live Data
12.00    0.50 (4.35%)
Bid:
11.50
Ask:
12.50
Spread: 1.00 (8.696%)
Market Cap: £15.02m
FAB Live PriceLast checked at - London Stock Exchange

Intraday Fusion Antibodies Share Chart

Appointment of Director

22 Jan 2007 07:01

Fabian Romania Property Fund Ltd22 January 2007 22 January 2007 Fabian Romania Property Fund Limited ("Fabian" or the "Fund") Resolution toAppoint a Director subject to formal approval of the Jersey Financial ServicesCommission ("JFSC") Fabian, the AIM listed property fund established to invest in Romanian property,has resolved to appoint Mark Houslop to the Board of Fabian subject to theapproval of the JFSC. Nicholas Mark Houslop, 58, joined the firm of surveyors DTC in 1973 and became apartner in 1979 and a Director in the company when it became publicly listed(DTZ) in London in 1987. His experience has extended from the UK and Europeanmarkets to the USA where he set up and ran the firm's New York office for fiveyears advising on major real estate investments in New York, Washington D.C,Houston, Denver, San Francisco and Los Angeles. In the UK he has advised on many central London properties including The Lloydsof London headquarters, The Berkeley Square Estate and The Plaza Shopping Centreand UK House both major blocks on Oxford Street, as well as developments inLondon Docklands. Mr Houslop sits on the supervisory board of the German publicly listedresidential/commercial property company IMW and is a fellow of the RoyalInstitution of Chartered Surveyors. Mark Houslop's conditional appointment marks a significant milestone in theimplementation of Fabian's strategy to bolster its Board following admission toAIM on December 15 last year. Commenting on today's appointment, Mark Holdsworth, Director of the Fund said: "Mark Houslop has over 30 year's experience of the property industry. He set upDTZ's US business. Mark will be a valuable addition to Fabian and we aredelighted to have him join the Board" Listed below are the names of all companies of which Mark Houslop has beendirector and all partnerships in which he has been a partner at any time in thepast five years: Current directorships and partnerships Past directorships and partnerships IMW Immobilien AG None There are no further details required to be disclosed in relation to thisappointment pursuant to Rule 17 and Schedule 2, paragraph (g) of the AIM Rules. For further information, please contact: Fabian Romania Property Fund LimitedMark Holdsworth 020 7499 9988 Shore Capital Stockbrokers LimitedDru Danford 020 7408 4090 Deloitte Corporate FinanceJames Lewis 020 7936 3000 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
1st Jul 20264:45 pmRNSHolding(s) in Company
30th Jun 20265:00 pmRNSTotal Voting Rights
22nd Jun 20267:00 amRNSNotice of allowance of patent in Canada
15th Jun 20267:00 amRNSUpdate on grant-funded DR5 project
2nd Jun 20267:00 amRNSExercise of options and total voting rights
11th May 20263:06 pmRNSHolding(s) in Company
11th May 202611:05 amRNSGrant of patent in Japan
5th May 20267:00 amRNSYear-end trading statement
30th Mar 20267:00 amRNSAntibody IP transfer agreement
17th Feb 202611:42 amRNSDirector/PDMR Shareholding
4th Feb 20263:27 pmRNSHolding(s) in Company
2nd Feb 202611:33 amRNSHolding(s) in Company
30th Jan 20265:00 pmRNSTotal Voting Rights
27th Jan 20267:05 amRNSIssue of Director Shares
27th Jan 20267:00 amRNSPlacing and Subscription to raise approx £1.4m
19th Dec 20257:00 amRNSUpdate on negotiations with NCI regarding OptiMAL
19th Dec 20257:00 amRNSUpdate on negotiations with NCI regarding OptiMAL
16th Dec 202511:04 amRNSLaunch of OptiMAL platform
11th Dec 20257:00 amRNS-RMammalian Display video
25th Nov 202512:11 pmRNSHolding(s) in Company
24th Nov 20257:00 amRNSHalf-year Financial Report
21st Nov 20257:00 amRNSNotice of Results
13th Nov 20257:00 amRNS-ROptiMAL Library video
3rd Nov 20257:00 amRNSOptiMAL® R&D Update
27th Oct 20253:38 pmRNSHolding(s) in Company
16th Oct 20251:31 pmRNSResult of AGM
16th Oct 20257:00 amRNSAGM statement and H1 trading update
8th Oct 20257:00 amRNSContract win
19th Sep 202512:58 pmRNSPosting of Annual Report & Notice of AGM
17th Sep 20257:00 amRNSOptiMAL R&D Update
8th Sep 20257:00 amRNS-RBelfast investor presentation
4th Sep 20257:00 amRNSFinal Results
28th Aug 20257:00 amRNSContract Win
27th Aug 20257:00 amRNSContract wins with existing client
26th Aug 20257:00 amRNS-RInvestor presentations
5th Aug 20257:00 amRNSGrant of U.S. Patent for OptiMAL
24th Jul 202510:56 amRNSIssue Notification: US Patent Update
11th Jul 20257:00 amRNSDirector/PDMR Shareholding
2nd Jun 20257:00 amRNSTotal Voting Rights
22nd May 20252:33 pmRNSUpdate on U.S. Patent for OptiMAL®
8th May 20257:00 amRNS-RInvestor presentation
7th May 20257:00 amRNSIssue of shares to non-executive directors
6th May 202510:53 amRNSDirector/PDMR Shareholding
6th May 202510:38 amRNSHolding(s) in Company
6th May 20257:00 amRNSTrading update
30th Apr 20255:00 pmRNSTotal Voting Rights
24th Apr 20257:00 amRNSApproval of grant funding
11th Apr 202510:40 amRNSHolding(s) in Company
10th Apr 202512:47 pmRNSHolding(s) in Company
7th Apr 202512:35 pmRNSResult of General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.